NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BPMC

Blueprint Medicines Corp

Jun 30 • 04:00PM ET

128.18

Dollar change +0.07
Percentage change 0.05	%

Healthcare • Biotechnology • USA • NASD

Peers: INCY EXEL SAGE TXMD GNFT BLUE TVRD DNLI BYSI MGNX

| Held by: VTI IWM VB VXF XBI VBK IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.46	Insider Own	3.67%	Shs Outstand	64.56M	Perf Week	-0.17%
Market Cap	8.29B	Forward P/E	139.55	EPS next Y	0.92	Insider Trans	-5.12%	Shs Float	62.27M	Perf Month	24.37%
Enterprise Value	8.43B	PEG	-	EPS next Q	-0.44	Inst Own	106.61%	Short Float	5.02%	Perf Quarter	44.48%
Income	-155.73M	P/S	14.75	EPS this Y	34.23%	Inst Trans	3.74%	Short Ratio	1.09	Perf Half Y	41.70%
Sales	562.12M	P/B	24.19	EPS next Y	230.52%	ROA	-13.94%	Short Interest	3.13M	Perf YTD	46.96%
Book/sh	5.30	P/C	14.38	EPS next 5Y	-	ROE	-47.71%	52W High	128.45 -0.21%	Perf Year	23.34%
Cash/sh	8.91	P/FCF	-	EPS past 3/5Y	54.06% 31.87%	ROIC	-16.74%	52W Low	73.04 75.49%	Perf 3Y	127.35%
Dividend Est.	0.33 (0.26%)	EV/EBITDA	-	Sales past 3/5Y	41.37% 50.22%	Gross Margin	93.65%	Volatility	0.16% 0.39%	Perf 5Y	62.38%
Dividend TTM	-	EV/Sales	14.99	EPS Y/Y TTM	48.43%	Oper. Margin	-31.01%	ATR (14)	1.61	Perf 10Y	286.90%
Dividend Ex-Date	-	Quick Ratio	2.75	Sales Y/Y TTM	99.19%	Profit Margin	-27.70%	RSI (14)	74.78	Recom	2.90
Dividend Gr. 3/5Y	- -	Current Ratio	2.80	EPS Q/Q	-99.46%	SMA20	0.08%	Beta	0.89	Target Price	130.60
Payout	-	Debt/Eq	2.08	Sales Q/Q	55.45%	SMA50	17.68%	Rel Volume	0.82	Prev Close	128.11
Employees	649	LT Debt/Eq	1.72	Earnings	May 01 BMO	SMA200	32.14%	Avg Volume	2.88M	Price	128.18
IPO	Apr 30, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	102.06% -3.91%	Trades		Volume	2,349,537	Change	0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Downgrade	Wedbush	Outperform → Neutral	$129
Mar-20-25	Resumed	Morgan Stanley	Equal-Weight	$100
Mar-18-25	Initiated	Wolfe Research	Outperform
Mar-17-25	Initiated	Jefferies	Buy	$135
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$150
Nov-14-24	Initiated	JP Morgan	Overweight	$126
Oct-24-24	Initiated	UBS	Neutral	$88
May-14-24	Initiated	Stephens	Overweight	$140
May-06-24	Upgrade	Leerink Partners	Underperform → Market Perform	$50 → $97
Oct-27-23	Upgrade	Oppenheimer	Perform → Outperform	$85
Aug-21-23	Reiterated	Needham	Buy	$65 → $66
Jul-31-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$55 → $82
Jun-05-23	Downgrade	SVB Securities	Market Perform → Underperform	$48 → $43
Jan-03-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$41
Dec-14-22	Initiated	Needham	Buy	$60
Nov-02-22	Downgrade	Oppenheimer	Outperform → Perform
Sep-14-22	Initiated	Berenberg	Buy	$90
Jul-08-22	Initiated	Oppenheimer	Outperform	$80
Jun-27-22	Initiated	Wells Fargo	Underweight	$40
Jun-10-22	Downgrade	Citigroup	Neutral → Sell	$68 → $41

Show Previous Ratings

Jun-24-25 12:45PM	Blueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic Mastocytosis (Insider Monkey)
Jun-12-25 06:01PM	Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT/AYVAKYT (avapritinib) Treatment at 2025 EHA and EAACI Congresses (PR Newswire)
Jun-06-25 11:31AM	Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report? (Zacks)
Jun-03-25 02:22AM	Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 04:41PM	These Stocks Are Moving the Most Today: Cleveland-Cliffs, Tesla, GM, Blueprint Medicines, BioNTech, DraftKings, and More (Barrons.com) +26.09%
01:39PM	Loading…
01:39PM	Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of (GuruFocus.com)
12:09PM	Top Stock Movers Now: Ford, Cleveland-Cliffs, Moderna, and More (Investopedia)
11:58AM	Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines (Zacks)
11:45AM	M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal (Yahoo Finance Video)
11:43AM	Sanofi to acquire Blueprint Medicines, Boeing upgrade (Yahoo Finance Video)
10:54AM	Sanofi to expand immunology offerings with Blueprint Medicines (Pharmaceutical Technology)
08:54AM	Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover (Investopedia)
08:12AM	Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout (Benzinga)
07:38AM	5 Things to Know Before the Stock Market Opens (Investopedia)
06:50AM	Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. (Barrons.com)
05:11AM	Loading…
05:11AM	Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline (The Wall Street Journal)
01:25AM	Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology (PR Newswire)
01:24AM	Sanofi to buy US biopharma group Blueprint for up to $9.5 billion (Reuters)
01:22AM	Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion (The Wall Street Journal)
May-24-25 06:02AM	Stay Invested: Wells Fargo Suggests 2 Stocks to Ride the Market Recovery (TipRanks)
May-02-25 12:21PM	Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings (Zacks) +5.43%
03:03AM	Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ... (GuruFocus.com)
01:22AM	Q1 2025 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents)
May-01-25 02:01PM	Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript (Seeking Alpha) +10.89%
08:25AM	Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:22AM	Blueprint Medicines: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance (PR Newswire)
Apr-29-25 11:59AM	Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
06:42AM	Can Amgen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-28-25 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
11:59AM	Loading…
Apr-25-25 11:59AM	CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
08:00AM	Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (PR Newswire)
Apr-24-25 10:01AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-23-25 08:47PM	Blueprint Medicines Corporation (BPMC): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
Apr-15-25 08:59AM	Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last? (Zacks)
Apr-07-25 05:37AM	Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth (Seeking Alpha)
Mar-31-25 08:00AM	Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-30-25 04:10PM	Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy? (Insider Monkey)
Mar-29-25 06:04AM	Blueprint Medicines: Strong Business, Ambitious Targets, Expensive Stock (Seeking Alpha)
Mar-25-25 09:18PM	Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-20-25 03:11PM	Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March (InsiderMonkey)
Mar-18-25 09:45AM	Reddit initiated, Netflix upgraded: Wall Streets top analyst calls (TipRanks)
Feb-28-25 08:00AM	Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress (PR Newswire) +6.80%
Feb-24-25 01:12PM	Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now (Insider Monkey)
Feb-14-25 02:09AM	Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ... (GuruFocus.com)
Feb-13-25 11:23PM	Q4 2024 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents) -8.08%
08:25AM	Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:21AM	Blueprint Medicines: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results (PR Newswire)
Feb-06-25 10:01AM	Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know (Zacks)
09:55AM	Should You Buy Blueprint Medicines (BPMC) After Golden Cross? (Zacks)
Feb-05-25 08:00AM	Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 (PR Newswire)
Jan-26-25 03:09AM	Why Blueprint Medical (BPMC) Is Skyrocketing Now (Insider Monkey)
Jan-14-25 04:43AM	Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar? (Zacks)
Jan-13-25 11:13AM	Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor (GuruFocus.com) +18.22%
Jan-12-25 04:00PM	Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth (PR Newswire)
Dec-18-24 08:00AM	Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-07-24 12:30PM	Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting (PR Newswire)
Nov-29-24 11:31AM	Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-14-24 03:18PM	Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst (Benzinga)
Oct-31-24 03:05AM	Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... (GuruFocus.com)
12:04AM	Q3 2024 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents)
Oct-30-24 08:10AM	Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.00%
07:10AM	Blueprint Medicines: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance (PR Newswire)
Oct-23-24 10:01AM	Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-21-24 12:00PM	Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-16-24 08:00AM	Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 (PR Newswire)
Oct-15-24 09:55AM	Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know (Zacks)
Sep-10-24 08:00AM	Blueprint Medicines to Present at Upcoming Investor Conferences (PR Newswire)
Aug-19-24 07:00PM	Insider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC) (GuruFocus.com)
Aug-09-24 09:55AM	Blueprint Medicines (BPMC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Aug-02-24 10:44AM	Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat (Zacks)
Aug-01-24 08:05AM	Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -7.40%
07:05AM	Blueprint Medicines: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance (PR Newswire)
Jul-25-24 10:02AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-18-24 08:00AM	Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 (PR Newswire)
Jun-25-24 12:39PM	How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park' (Investor's Business Daily)
Jun-07-24 09:15PM	Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC) (GuruFocus.com)
Jun-06-24 07:01PM	Insider Sale at Blueprint Medicines Corp (BPMC): Chief Medical Officer L. Hewes Sells Shares (GuruFocus.com)
May-30-24 06:01PM	Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT/AYVAKYT (avapritinib) (PR Newswire) +5.76%
May-23-24 05:05PM	Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting (PR Newswire)
May-14-24 07:50AM	Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target (MT Newswires)
May-06-24 05:32PM	Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing (MT Newswires)
04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
11:45AM	Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating (MT Newswires)
07:05AM	Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97 (MT Newswires)
May-03-24 10:03AM	Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:51AM	Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises (Zacks)
03:05AM	Blueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ... (GuruFocus.com)
May-02-24 09:24PM	Q1 2024 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents) +12.80%
11:56AM	BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:56AM	Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating (MT Newswires)
10:16AM	Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises (MT Newswires)
08:36AM	Blueprint Medicines Corp Reports Q1 2024 Earnings, Surpasses Revenue Estimates and Raises ... (GuruFocus.com)
08:10AM	Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:11AM	Blueprint Medicines: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance (PR Newswire)
Apr-25-24 10:01AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)

Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carter Percy H.	CHIEF SCIENTIFIC OFFICER	Jun 03 '25	Sale	127.88	2,659	340,033	54,206	Jun 05 04:22 PM
Albers Jeffrey W.	Director	May 27 '25	Option Exercise	36.05	5,000	180,250	151,630	May 29 04:20 PM
Albers Jeffrey W.	Director	May 27 '25	Sale	101.14	5,000	505,692	146,630	May 29 04:20 PM
Albers Jeffrey W.	Director	May 27 '25	Proposed Sale	101.14	5,000	505,686		May 27 09:06 PM
Rossi Christina	CHIEF OPERATING OFFICER	May 19 '25	Sale	100.51	2,274	228,557	64,718	May 21 04:33 PM
Rossi Christina	CHIEF OPERATING OFFICER	May 05 '25	Sale	101.75	2,274	231,386	66,992	May 07 04:32 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	May 05 '25	Option Exercise	54.13	2,752	148,966	19,696	May 07 04:30 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	May 05 '25	Sale	103.13	2,752	283,819	16,944	May 07 04:30 PM
ARIEL HURLEY	Officer	May 05 '25	Proposed Sale	104.64	2,942	307,851		May 05 04:57 PM
Haviland Kate	CHIEF EXECUTIVE OFFICER	Apr 01 '25	Sale	86.65	2,498	216,461	165,929	Apr 03 04:30 PM
KATHRYN D HAVILAND	Officer	Apr 01 '25	Proposed Sale	88.51	2,498	221,098		Apr 01 04:20 PM
Rossi Christina	CHIEF OPERATING OFFICER	Mar 24 '25	Sale	95.02	2,274	216,075	69,266	Mar 26 04:27 PM
Christina Rossi	Officer	Mar 24 '25	Proposed Sale	89.20	9,096	811,363		Mar 24 05:04 PM
Albers Jeffrey W.	Director	Mar 05 '25	Sale	88.80	5,766	512,021	146,630	Mar 17 04:26 PM
Albers Jeffrey W.	Director	Mar 12 '25	Option Exercise	36.05	7,500	270,375	159,896	Mar 14 04:36 PM
Albers Jeffrey W.	Director	Mar 12 '25	Sale	87.80	7,500	658,500	152,396	Mar 14 04:36 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	Mar 06 '25	Sale	87.69	5,232	458,804	30,419	Mar 07 04:15 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	Mar 05 '25	Sale	88.80	4,863	431,834	35,651	Mar 07 04:15 PM
Rossi Christina	CHIEF OPERATING OFFICER	Mar 05 '25	Sale	88.80	6,495	576,756	71,540	Mar 07 04:14 PM
Namouni Fouad	PRESIDENT, R & D	Mar 05 '25	Sale	88.80	6,489	576,223	75,781	Mar 07 04:13 PM
McCain Tracey L	EVP AND CHIEF LEGAL OFFICER	Mar 05 '25	Sale	88.80	5,262	467,266	66,583	Mar 07 04:12 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Mar 05 '25	Sale	88.80	3,733	331,490	41,996	Mar 07 04:11 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 05 '25	Sale	88.80	5,284	469,219	72,924	Mar 07 04:10 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 05 '25	Sale	88.80	1,326	117,749	16,944	Mar 07 04:09 PM
Haviland Kate	CHIEF EXECUTIVE OFFICER	Mar 05 '25	Sale	88.80	16,151	1,434,209	168,427	Mar 07 04:08 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Mar 05 '25	Sale	88.80	5,157	457,942	49,606	Mar 07 04:07 PM
Carter Percy H.	CHIEF SCIENTIFIC OFFICER	Mar 05 '25	Sale	88.80	3,530	313,464	56,865	Mar 07 04:06 PM
LEMUEL BECKER HEWES	Officer	Mar 06 '25	Proposed Sale	87.69	5,232	458,804		Mar 06 04:19 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 03 '25	Sale	92.62	3,203	296,666	18,270	Mar 04 05:20 PM
ARIEL HURLEY	Officer	Mar 03 '25	Proposed Sale	96.57	2,250	217,282		Mar 03 04:15 PM
Rossi Christina	CHIEF OPERATING OFFICER	Feb 20 '25	Sale	95.14	2,274	216,348	64,835	Feb 24 04:15 PM
Haviland Kate	CHIEF EXECUTIVE OFFICER	Jan 21 '25	Sale	110.24	1,446	159,407	149,378	Jan 23 07:56 PM
Rossi Christina	CHIEF OPERATING OFFICER	Jan 21 '25	Sale	110.14	2,274	250,455	67,109	Jan 23 07:54 PM
Albers Jeffrey W.	Director	Jan 21 '25	Option Exercise	36.05	10,000	360,500	167,557	Jan 23 07:53 PM
Albers Jeffrey W.	Director	Jan 21 '25	Sale	109.53	15,161	1,660,511	152,396	Jan 23 07:53 PM
CHRISTOPHER MURRAY	Officer	Jan 23 '25	Proposed Sale	111.08	2,500	277,700		Jan 23 04:23 PM
Albers Jeffrey W.	Director	Jan 21 '25	Proposed Sale	109.79	5,161	566,627		Jan 21 09:25 PM
CHRISTOPHER MURRAY	Officer	Jan 17 '25	Proposed Sale	103.95	2,500	259,875		Jan 17 04:24 PM
Albers Jeffrey W.	Director	Jan 13 '25	Option Exercise	36.05	5,000	180,250	162,557	Jan 15 06:04 PM
Albers Jeffrey W.	Director	Jan 13 '25	Sale	102.28	5,000	511,400	157,557	Jan 15 06:04 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Jan 13 '25	Option Exercise	36.05	2,250	81,112	17,217	Jan 15 06:03 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Jan 13 '25	Sale	100.00	2,250	225,000	14,967	Jan 15 06:03 PM
Albers Jeffrey W.	Director	Jan 13 '25	Proposed Sale	102.28	5,000	511,398		Jan 14 04:50 PM
Albers Jeffrey W.	Director	Dec 19 '24	Option Exercise	36.05	15,000	540,750	172,557	Dec 20 04:15 PM
Albers Jeffrey W.	Director	Dec 19 '24	Sale	89.77	15,000	1,346,615	157,557	Dec 20 04:15 PM
Rossi Christina	CHIEF OPERATING OFFICER	Dec 18 '24	Sale	95.91	2,274	218,098	69,383	Dec 20 04:15 PM
Albers Jeffrey W.	Director	Dec 19 '24	Proposed Sale	89.78	15,000	1,346,633		Dec 19 05:17 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 12 '24	Option Exercise	15.01	1,600	24,016	16,786	Dec 16 07:51 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 12 '24	Sale	93.26	1,819	169,636	14,967	Dec 16 07:51 PM
ARIEL HURLEY	Officer	Dec 12 '24	Proposed Sale	94.47	5,022	474,428		Dec 12 04:52 PM
Haviland Kate	CHIEF EXECUTIVE OFFICER	Nov 29 '24	Sale	96.60	2,353	227,304	150,824	Dec 03 05:33 PM
Rossi Christina	CHIEF OPERATING OFFICER	Nov 27 '24	Sale	95.10	2,274	216,257	71,657	Dec 02 06:52 PM
KATHRYN D HAVILAND	Officer	Nov 29 '24	Proposed Sale	95.10	3,799	361,285		Nov 29 01:40 PM
Christina Rossi and Gregory Pa	Affiliate	Nov 27 '24	Proposed Sale	94.63	9,096	860,754		Nov 27 06:51 PM
COATS LONNEL	Director	Nov 20 '24	Option Exercise	70.75	8,812	623,452	22,066	Nov 22 04:47 PM
COATS LONNEL	Director	Nov 20 '24	Sale	93.77	10,000	937,655	12,066	Nov 22 04:47 PM
COATS LONNEL	Director	Nov 21 '24	Sale	94.87	9,824	932,003	2,242	Nov 22 04:47 PM
LONNEL COATS	Director	Nov 21 '24	Proposed Sale	94.81	9,824	931,413		Nov 21 04:23 PM
LONNEL COATS	Director	Nov 20 '24	Proposed Sale	94.60	10,000	946,000		Nov 20 04:30 PM
Albers Jeffrey W.	Director	Nov 07 '24	Option Exercise	36.05	5,000	180,250	162,557	Nov 12 04:15 PM
Albers Jeffrey W.	Director	Nov 07 '24	Sale	102.00	5,000	510,000	157,557	Nov 12 04:15 PM
Albers Jeffrey W.	Director	Nov 07 '24	Proposed Sale	102.00	5,000	510,000		Nov 07 05:24 PM
Namouni Fouad	PRESIDENT, R & D	Oct 03 '24	Sale	89.32	3,633	324,500	69,070	Oct 04 05:09 PM
Albers Jeffrey W.	Director	Sep 09 '24	Option Exercise	36.05	10,000	360,500	177,259	Sep 11 04:06 PM
Albers Jeffrey W.	Director	Sep 09 '24	Sale	85.57	19,702	1,685,891	157,557	Sep 11 04:06 PM
Albers Jeffrey W.	Director	Sep 09 '24	Proposed Sale	85.57	19,702	1,685,911		Sep 09 09:22 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Aug 15 '24	Sale	95.23	4,409	419,869	67,208	Aug 19 04:00 PM
MICHAEL LANDSITTEL	Officer	Aug 15 '24	Proposed Sale	95.23	4,409	419,891		Aug 15 04:27 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Aug 05 '24	Option Exercise	67.50	41,913	2,828,921	76,642	Aug 07 05:06 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Aug 05 '24	Sale	93.19	41,913	3,905,872	34,729	Aug 07 05:06 PM
Lee Philina	Officer	Aug 05 '24	Proposed Sale	93.00	46,436	4,318,548		Aug 05 04:50 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 03 '24	Option Exercise	54.13	8,817	477,264	52,580	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 05 '24	Option Exercise	54.13	3,850	208,400	47,613	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 03 '24	Sale	111.29	8,817	981,244	43,763	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 05 '24	Sale	111.20	3,850	428,120	43,763	Jul 08 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BPMC

Blueprint Medicines Corp

Upgrade your FINVIZ experience